Published in Adv Drug Deliv Rev on August 04, 2010
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. Chem Rev (2014) 1.68
Noble metal nanoparticles applications in cancer. J Drug Deliv (2011) 1.66
Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater (2012) 1.56
Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano (2013) 1.44
Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev (2011) 1.36
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics (2014) 1.29
Liposomes as nanomedical devices. Int J Nanomedicine (2015) 1.29
Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett (2011) 1.24
Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics (2012) 1.24
Informatics and standards for nanomedicine technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 1.19
A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun (2014) 1.17
FUNCTIONAL NANOPARTICLES FOR MOLECULAR IMAGING GUIDED GENE DELIVERY. Nano Today (2010) 1.15
Gold nanorods based platforms for light-mediated theranostics. Theranostics (2013) 1.11
HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. Mol Pharm (2011) 1.11
Evaluating the pharmacokinetics and in vivo cancer targeting capability of Au nanocages by positron emission tomography imaging. ACS Nano (2012) 1.10
Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release (2011) 1.09
Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging. Theranostics (2012) 1.09
Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy. J Am Chem Soc (2011) 1.09
Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev (2013) 1.07
Triphase interface synthesis of plasmonic gold bellflowers as near-infrared light mediated acoustic and thermal theranostics. J Am Chem Soc (2014) 1.06
Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J Control Release (2013) 1.05
Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol (2014) 1.05
Nanobody: the "magic bullet" for molecular imaging? Theranostics (2014) 1.04
Biocomputing based on particle disassembly. Nat Nanotechnol (2014) 1.03
Theranostic nanoparticles. J Nucl Med (2014) 1.03
Nanoparticle preconditioning for enhanced thermal therapies in cancer. Nanomedicine (Lond) (2011) 1.03
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging (2011) 1.01
Iron oxide decorated MoS2 nanosheets with double PEGylation for chelator-free radiolabeling and multimodal imaging guided photothermal therapy. ACS Nano (2015) 0.99
Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev (2012) 0.97
Nanoparticles for imaging: top or flop? Radiology (2014) 0.97
Nanotheranostics for personalized medicine. Expert Rev Mol Diagn (2013) 0.96
Manipulating the power of an additional phase: a flower-like Au-Fe3O4 optical nanosensor for imaging protease expressions in vivo. ACS Nano (2011) 0.95
Nanotechnology-based approaches in anticancer research. Int J Nanomedicine (2012) 0.93
Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field. Int J Nanomedicine (2014) 0.93
Enhanced blood-brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology (2014) 0.93
Nano delivers big: designing molecular missiles for cancer therapeutics. Pharmaceutics (2011) 0.91
Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of human hepatocellular carcinoma. Contrast Media Mol Imaging (2012) 0.90
Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens. Nat Chem (2015) 0.90
Phase-shift, stimuli-responsive drug carriers for targeted delivery. Ther Deliv (2011) 0.90
A Green Synthesis of Carbon Nanoparticle from Honey for Real-Time Photoacoustic Imaging. Nano Res (2013) 0.88
Delivery of cancer therapeutics using nanotechnology. Pharmaceutics (2013) 0.88
Multifunctional gold nanorods for siRNA gene silencing and photothermal therapy. Adv Healthc Mater (2014) 0.87
Nanoparticles for Improving Cancer Diagnosis. Mater Sci Eng R Rep (2013) 0.87
Trackable and Targeted Phage as Positron Emission Tomography (PET) Agent for Cancer Imaging. Theranostics (2011) 0.87
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine. ACS Nano (2015) 0.86
A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy. Theranostics (2015) 0.85
Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects. Chem Rev (2015) 0.85
Inorganic nanosystems for therapeutic delivery: status and prospects. Adv Drug Deliv Rev (2012) 0.85
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging (2015) 0.85
Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles. Adv Drug Deliv Rev (2014) 0.84
Role of Albumin in the Formation and Stabilization of Nanoparticle Aggregates in Serum Studied by Continuous Photon Correlation Spectroscopy and Multiscale Computer Simulations. J Phys Chem C Nanomater Interfaces (2014) 0.83
Design and Application of Magnetic-based Theranostic Nanoparticle Systems. Recent Pat Biomed Eng (2013) 0.83
Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol (2011) 0.83
Cell-penetrating peptide enhanced intracellular Raman imaging and photodynamic therapy. Mol Pharm (2013) 0.83
Theranostic Imaging of Yttrium-90. Biomed Res Int (2015) 0.83
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett (2012) 0.82
FeSe2-Decorated Bi2Se3 Nanosheets Fabricated via Cation Exchange for Chelator-Free (64)Cu-labeling and Multimodal Image-Guided Photothermal-Radiation Therapy. Adv Funct Mater (2016) 0.82
Potential dual imaging nanoparticle: Gd2O3 nanoparticle. Sci Rep (2015) 0.82
Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. Int J Nanomedicine (2012) 0.81
Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces (2014) 0.81
Study on performance of magnetic fluorescent nanoparticles as gene carrier and location in pig kidney cells. Nanoscale Res Lett (2013) 0.81
A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo. Nat Protoc (2014) 0.81
Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars. Nanomedicine (2014) 0.81
Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol (2015) 0.81
Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles. Nanoscale (2015) 0.81
Theranostic cRGD-BioShuttle Constructs Containing Temozolomide- and Cy7 For NIR-Imaging and Therapy. Theranostics (2011) 0.80
Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform. Theranostics (2016) 0.80
Multivalent polymers for drug delivery and imaging: the challenges of conjugation. Biomacromolecules (2014) 0.80
Diverse Applications of Nanomedicine. ACS Nano (2017) 0.80
Label-free luminescent mesoporous silica nanoparticles for imaging and drug delivery. Theranostics (2013) 0.79
Cytotoxicity evaluation of carbon-encapsulated iron nanoparticles in melanoma cells and dermal fibroblasts. J Nanopart Res (2013) 0.79
Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs. ACS Nano (2015) 0.78
Direct Thrombus Imaging in Stroke. J Stroke (2016) 0.78
Recent Advances in Nanomaterials for Gene Delivery-A Review. Nanomaterials (Basel) (2017) 0.78
A novel redox-sensitive system based on single-walled carbon nanotubes for chemo-photothermal therapy and magnetic resonance imaging. Int J Nanomedicine (2016) 0.78
Inhibition of Osteoclast Differentiation and Bone Resorption by Bisphosphonate-conjugated Gold Nanoparticles. Sci Rep (2016) 0.78
Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy. Theranostics (2016) 0.78
Multimodal iron oxide nanoparticles for hybrid biomedical imaging. NMR Biomed (2012) 0.78
Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharm Investig (2015) 0.78
A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer's disease. Chem Commun (Camb) (2014) 0.78
Effects of nanoparticle size on antitumor activity of 10-hydroxycamptothecin-conjugated gold nanoparticles: in vitro and in vivo studies. Int J Nanomedicine (2016) 0.78
An Overview of Multimodal Neuroimaging Using Nanoprobes. Int J Mol Sci (2017) 0.77
Lanthanide-Doped Upconversion Nanoparticles: Emerging Intelligent Light-Activated Drug Delivery Systems. Adv Sci (Weinh) (2016) 0.77
S-layer fusion protein as a tool functionalizing emulsomes and CurcuEmulsomes for antibody binding and targeting. Colloids Surf B Biointerfaces (2015) 0.77
Biosensing with Förster Resonance Energy Transfer Coupling between Fluorophores and Nanocarbon Allotropes. Sensors (Basel) (2015) 0.77
Protein and peptide probes for molecular imaging. Amino Acids (2011) 0.77
Nucleic Acid-directed Self-assembly of Multifunctional Gold Nanoparticle Imaging Agents. Biomater Sci (2013) 0.77
Theranostics: A treasured tailor for tomorrow. J Pharm Bioallied Sci (2014) 0.77
Covalent IR820-PEG-diamine nanoconjugates for theranostic applications in cancer. Int J Nanomedicine (2014) 0.77
Application of fluorescent nanoparticles to study remodeling of the endo-lysosomal system by intracellular bacteria. J Vis Exp (2015) 0.77
A peptide & peptide nucleic acid synthesis technology for transporter molecules and theranostics--the SPPS. Int J Med Sci (2014) 0.77
Enhanced bioavailability of apigenin via preparation of a carbon nanopowder solid dispersion. Int J Nanomedicine (2014) 0.77
BioShuttle mobility in living cells studied with high-resolution FCS & CLSM methodologies. Int J Med Sci (2012) 0.77
Multifunctional gold nanostars for molecular imaging and cancer therapy. Front Chem (2015) 0.77
Photothermal and photodynamic activity of polymeric nanoparticles based on α-tocopheryl succinate-RAFT block copolymers conjugated to IR-780. Acta Biomater (2017) 0.76
Gold Nanotheranostics: Proof-of-Concept or Clinical Tool? Nanomaterials (Basel) (2015) 0.76
Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.76
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev (2004) 13.49
Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater (2005) 12.97
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2003) 11.09
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials (2005) 11.01
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science (2002) 8.80
Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U S A (2005) 7.70
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med (2006) 7.05
Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science (2006) 6.42
Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed Engl (2007) 6.32
In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 4.94
Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater (2009) 4.77
Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev (2006) 4.69
DNA-assisted dispersion and separation of carbon nanotubes. Nat Mater (2003) 4.65
Noninvasive imaging of quantum dots in mice. Bioconjug Chem (2004) 4.59
Gold nanostructures: engineering their plasmonic properties for biomedical applications. Chem Soc Rev (2006) 4.52
Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization. J Am Chem Soc (2001) 4.46
A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat Nanotechnol (2008) 4.43
High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem (1999) 4.41
Anisotropic metal nanoparticles: Synthesis, assembly, and optical applications. J Phys Chem B (2005) 4.16
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett (2005) 3.96
Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into Mammalian cells. J Am Chem Soc (2004) 3.92
Nanotechnology applications in cancer. Annu Rev Biomed Eng (2007) 3.88
Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev (2008) 3.80
Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv (2004) 3.65
Carbon Nanotubes in Biology and Medicine: In vitro and in vivo Detection, Imaging and Drug Delivery. Nano Res (2009) 3.63
Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res (2008) 3.47
Bioactivation and cell targeting of semiconductor CdSe/ZnS nanocrystals with phytochelatin-related peptides. J Am Chem Soc (2004) 3.40
Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev (2008) 3.18
Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. Angew Chem Int Ed Engl (2006) 3.17
Biomedical applications of functionalised carbon nanotubes. Chem Commun (Camb) (2004) 3.10
Gold nanocages: synthesis, properties, and applications. Acc Chem Res (2008) 3.03
Fullerene pipes Science (1998) 2.99
Mesoporous materials for drug delivery. Angew Chem Int Ed Engl (2007) 2.93
Structure-based carbon nanotube sorting by sequence-dependent DNA assembly. Science (2003) 2.90
Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc (2003) 2.88
In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc (2005) 2.83
Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng (2005) 2.81
Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc (2005) 2.80
Bright and stable core-shell fluorescent silica nanoparticles. Nano Lett (2005) 2.79
Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc (2008) 2.79
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
Fluorescence resonance energy transfer between quantum dot donors and dye-labeled protein acceptors. J Am Chem Soc (2004) 2.72
A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc (2003) 2.69
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Oligomeric ligands for luminescent and stable nanocrystal quantum dots. J Am Chem Soc (2003) 2.68
Size series of small indium arsenide-zinc selenide core-shell nanocrystals and their application to in vivo imaging. J Am Chem Soc (2006) 2.65
siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl (2007) 2.61
Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol (2007) 2.57
Selective probing and imaging of cells with single walled carbon nanotubes as near-infrared fluorescent molecules. Nano Lett (2008) 2.51
A quantum dot conjugated sugar ball and its cellular uptake. On the size effects of endocytosis in the subviral region. J Am Chem Soc (2004) 2.49
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc (2008) 2.40
Nanoscaling laws of magnetic nanoparticles and their applicabilities in biomedical sciences. Acc Chem Res (2008) 2.37
Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A (2003) 2.37
Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew Chem Int Ed Engl (2004) 2.36
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem (2007) 2.31
Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin Cancer Res (2009) 2.22
Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc (2008) 2.21
Silica-coated nanocomposites of magnetic nanoparticles and quantum dots. J Am Chem Soc (2005) 2.18
Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir (2005) 2.14
Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul (1997) 2.08
Cancer cells assemble and align gold nanorods conjugated to antibodies to produce highly enhanced, sharp, and polarized surface Raman spectra: a potential cancer diagnostic marker. Nano Lett (2007) 2.04
Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew Chem Int Ed Engl (2005) 2.02
Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. J Am Chem Soc (2005) 1.97
Semiconductor quantum dots for photodynamic therapy. J Am Chem Soc (2003) 1.94
Paclitaxel-functionalized gold nanoparticles. J Am Chem Soc (2007) 1.94
Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl (2008) 1.94
Gold nanocages as photothermal transducers for cancer treatment. Small (2010) 1.92
Bifunctional magnetic silica nanoparticles for highly efficient human stem cell labeling. Nano Lett (2007) 1.91
In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. ACS Nano (2009) 1.88
Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small (2006) 1.88
Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc (2007) 1.86
Magnetic nanoparticles and their applications in medicine. Nanomedicine (Lond) (2006) 1.82
Engineering InAs(x)P(1-x)/InP/ZnSe III-V alloyed core/shell quantum dots for the near-infrared. J Am Chem Soc (2005) 1.79
All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl (2009) 1.77
A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc (2004) 1.73
A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat Nanotechnol (2009) 1.72
Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed Engl (2008) 1.71
Single-particle tracking of endocytosis and exocytosis of single-walled carbon nanotubes in NIH-3T3 cells. Nano Lett (2008) 1.70
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials (2008) 1.70
Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem (2002) 1.68
Semiconductor quantum dots and metal nanoparticles: syntheses, optical properties, and biological applications. Anal Bioanal Chem (2008) 1.66
Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica. Nature (2003) 1.66
Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer (2007) 1.65
Multiplexed multicolor Raman imaging of live cells with isotopically modified single walled carbon nanotubes. J Am Chem Soc (2008) 1.65
Probing the structure of DNA-carbon nanotube hybrids with molecular dynamics. Nano Lett (2007) 1.65
Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem (2009) 1.63
Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res (2010) 1.60
Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials (2010) 1.59
Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere. J Am Chem Soc (2009) 1.58
Quantum dot-amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA. ACS Nano (2008) 1.53
Magnetic fluorescent delivery vehicle using uniform mesoporous silica spheres embedded with monodisperse magnetic and semiconductor nanocrystals. J Am Chem Soc (2006) 1.51
Peptide-conjugated gold nanorods for nuclear targeting. Bioconjug Chem (2007) 1.50
Hybrid silica nanoparticles for multimodal imaging. Angew Chem Int Ed Engl (2007) 1.50
Bifunctional Gold Nanoshells with a Superparamagnetic Iron Oxide-Silica Core Suitable for Both MR Imaging and Photothermal Therapy. J Phys Chem C Nanomater Interfaces (2007) 1.49
High-thermoelectric performance of nanostructured bismuth antimony telluride bulk alloys. Science (2008) 7.34
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol (2008) 6.41
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res (2008) 3.47
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med (2007) 2.86
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 2.31
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett (2010) 2.00
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc (2008) 1.89
Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 1.87
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther (2006) 1.81
Pulse accumulation, radial heat conduction, and anisotropic thermal conductivity in pump-probe transient thermoreflectance. Rev Sci Instrum (2008) 1.80
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
Unusual magnetic properties of one-dimensional molecule-based magnets associated with a structural phase transition. Inorg Chem (2002) 1.78
Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem (2006) 1.75
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. Chem Rev (2014) 1.68
Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem (2007) 1.64
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem (2006) 1.64
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology (2011) 1.59
Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells (2009) 1.58
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem (2011) 1.56
Oxorhenium(V) complexes containing tridentate Schiff-base and monothiol coligands. Inorganica Chim Acta (2000) 1.56
Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater (2012) 1.56
Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging (2008) 1.55
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol (2009) 1.49
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano (2010) 1.46
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med (2013) 1.44
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl (2009) 1.44
Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano (2013) 1.44
Peptide-based probes for targeted molecular imaging. Biochemistry (2010) 1.43
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials (2009) 1.42
A strategy for the proliferation of Ulva prolifera, main causative species of green tides, with formation of sporangia by fragmentation. PLoS One (2010) 1.42
Integrin targeted delivery of chemotherapeutics. Theranostics (2011) 1.42
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem (2007) 1.39
Ultrasmall near-infrared non-cadmium quantum dots for in vivo tumor imaging. Small (2010) 1.38
Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release (2008) 1.38
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release (2010) 1.37
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Protease-activated drug development. Theranostics (2012) 1.36
Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem (2009) 1.36
PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med (2009) 1.36
Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging (2009) 1.35
Short hairpin RNA interference therapy for ischemic heart disease. Circulation (2008) 1.34
Dual-modality probes for in vivo molecular imaging. Mol Imaging (2009) 1.34
Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci (2007) 1.33
Unusual magnetic property associated with dimerization within a nickel tetramer. Inorg Chem (2002) 1.33
Single continuous wave laser induced photodynamic/plasmonic photothermal therapy using photosensitizer-functionalized gold nanostars. Adv Mater (2013) 1.31
Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging (2009) 1.30
Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett (2007) 1.30
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release (2007) 1.29
18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med (2008) 1.29
Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med (2009) 1.29
Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. Nano Lett (2009) 1.29
Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res (2009) 1.28
(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging (2009) 1.28
18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med (2010) 1.28
Real-time video imaging of protease expression in vivo. Theranostics (2011) 1.27
18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging (2011) 1.26
First experience with clinical-grade ([18F]FPP(RGD₂): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol (2012) 1.26
Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging (2007) 1.26
Limb remote ischemic postconditioning protects against focal ischemia in rats. Brain Res (2009) 1.26
Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med (2007) 1.26
Family of enhanced photoacoustic imaging agents for high-sensitivity and multiplexing studies in living mice. ACS Nano (2012) 1.26